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ORIGINAL ARTICLE
Immunogenicity and protective efficacy of recombinant
Clostridium difficile flagellar protein FliC
Chandrabali Ghose1, Ioannis Eugenis1, Xingmin Sun2, Adrianne N Edwards3, Shonna M McBride3,
David T Pride4, Ciara´n P Kelly5 and David D Ho1,6
Clostridium difficile is a Gram-positive bacillus and is the leading cause of toxin-mediated nosocomial diarrhea following antibiotic
use. C. difficile flagella play a role in colonization, adherence, biofilm formation, and toxin production, which might contribute to the
overall virulence of certain strains. Human and animal studies indicate that anti-flagella immune responses may play a role in
protection against colonization by C. difficile and subsequent disease outcome. Here we report that recombinant C. difficile flagellin
(FliC) is immunogenic and protective in a murine model of C. difficile infection (CDI) against a clinical C. difficile strain, UK1. Passive
protection experiments using anti-FliC polyclonal serum in mice suggest this protection to be antibody-mediated. FliC immunization
also was able to afford partial protection against CDI and death in hamsters following challengewithC. difficile630Derm. Additionally,
immunization against FliC does not have an adverse effect on the normal gut flora of vaccinated hamsters as evidenced by
comparing the fecal microbiome of vaccinated and control hamsters. Therefore, the use of FliC as a vaccine candidate against CDI
warrants further testing.
Emerging Microbes and Infections (2016) 5, e8; doi:10.1038/emi.2016.8; published online 3 February 2016
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INTRODUCTION
Clostridium difficile is the causative agent of nosocomial, antibiotic-
associated infectious diarrhea. With the emergence of an epidemic
strain of C. difficile (BI/NAP1/027) in the last decade, C. difficile infec-
tion (CDI) is now associated with a high rate of mortality.1
Symptomatic disease is caused by the actions of C. difficile’s two major
toxins, toxin A (TcdA) and toxin B (TcdB), and the binary toxin (CDT)
that is expressed by certain epidemic C. difficile strains.2,3 Antibodies
against C. difficile are present in a majority of adults and older children
through the transient exposure to C. difficile, possibly at infancy.4,5 No
effective vaccine is commercially available although clinical evidence
indicates that host immunity against C. difficile TcdA and TcdB in the
form of toxin-neutralizing antibodies is protective.6,7 However,
immune responses against toxins do not prevent colonization by
C. difficile.6,8,9
As host immune responses to toxins play an important role in disease
outcomes, recent studies have looked at the presence of adaptive
immune responses to non-toxin virulence factors such as the S-layer
proteins, cell wall proteins, and flagella in CDI patients.10,11 These stud-
ies show that antibody levels against surface proteins, such as flagella
and cell wall protease 84 (Cwp84), were significantly higher in hospi-
talized patients who did not develop CDI than in a CDI patient group,
suggesting a possible protective role of such immune responses.
Several studies have reported that flagellar proteins are highly
immunogenic and that natural anti-flagella immune responses may
play a role in protection against colonization.12 Adherence of non-
flagellated strains of C. difficile to mouse cecum is 10-fold lower than
for flagellated strains.13 Furthermore, flagellar protein-immunized
mice showed reduced intestinal colonization by C. difficile.10
However, the role of flagella in the pathogenesis of C. difficile is com-
plex, with recent studies providing new insights into the role of flagella
not only in motility, but also in colonization, toxin gene expression,
and biofilm formation.14,15
The C. difficile flagellum is composed of a membrane-bound basal
body, a helicoidal filament and a hook. The 39 kDa flagellin, FliC, and
the 56 kDa flagellar cap protein, FliD, are two components of the
C. difficile flagellum.16–18 fliC and fliD are present on the F1 gene locus
of the flagellar regulon, part of a cluster of late-stage flagellar genes.19
fliC and fliD are present and transcribed in all strains, either flagellated
or non-flagellated, in in vitro culture. Thus, ‘non-flagellated’ strains
may possess cryptic fliC and fliD genes selectively expressed under
certain in vivo conditions during host–pathogen interaction and
may be essential for colonization.20 Conversely, recent analysis also
shows that disease-causing epidemic 078 ribotype strains lack flagella.3
C. difficile FliC is well conserved in the N- and C-terminal regions,
which are responsible for polymerization and secretion of FliC,
whereas the central surface exposed region is variable.17 Although
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the central domain is divergent, polyclonal antibodies raised against
FliC of one C. difficile strain react to FliC of other C. difficile strains,
suggesting shared cross-reacting immunologic epitopes, in contrast to
strains ofClostridium sordellii and Bacillus subtilis, which do not cross-
react to C. difficile FliC.16 These observations suggest the presence of
conserved cross-reactive elements within C. difficile FliC that is not
typical for flagellar proteins in other species.
It has also been reported that C. difficile FliC is able to activate the
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB)
pathway via signaling throughToll-like receptor-5 (TLR5).21 TLRs are a
family of pattern recognition receptors that recognize structural com-
ponents shared by bacteria, fungi, and viruses. TLRs, when bound to
their ligands such as FliC, may trigger innate and adaptive immune
responses, as well as facilitate the development of adaptive immunity
through various mechanisms, such as the activation and maturation of
dendritic cells and the expression of cytokines and other co-stimulatory
proteins.22 The Salmonella enterica serovarTyphimurium FliC has prev-
iously been used with partial success as an adjuvant in experimental
vaccines against influenza virus, Vibrio cholerae, and malaria.23–25
Recently, it has been reported that S. Typhimurium FliC-mediated
stimulation of TLR5 in mice protects them from death during CDI
by delaying C. difficile growth and toxin production in the gut.26
Whether C. difficile FliC-mediated activation of TLR5 can play a sig-
nificant role in responses against C. difficile and its disease outcome is
unknown.
We hypothesized that active immunization of a susceptible host
using C. difficile flagellar components could provide both a preventive
and a therapeutic vaccine strategy. In this study, we report that recom-
binant C. difficile flagellar protein FliC is immunogenic in mice, and
immunizationwith FliC is protective in amurinemodel of CDI during
challenge with a clinicalC. difficile strain, UK1. Protection against CDI
in mice following the passive transfer of anti-FliC polyclonal sera
suggests that this protection is antibody-mediated. In addition, FliC
was able to afford partial protection in a hamster model of CDI. These
results suggest that a recombinant C. difficile FliC is an attractive
candidate for further development and evaluation for active and pass-
ive immunization.
MATERIALS AND METHODS
Bacterial strains
Escherichia coli DH5a and E. coli BL21DE3* (Life Technologies,
Carlsbad, CA) were used for subcloning and recombinant protein puri-
fication, respectively. C. difficile UK1 (a 027/B1/NAP1 strain, kindly
provided by Dale Gerding), a clinical strain isolated during a 2006
outbreak at Stoke-Mandeville hospital in the UK, was used for the
bacterial challenge experiments inmice.27C. difficile 630Derm (ribotype
012) was used for the bacterial challenge experiments in hamsters.
C. difficile 630Derm is a spontaneous erythromycin-sensitive derivative
of the parental reference strain 630 obtained by serial passaging in
antibiotic-free media.28 It is well defined and widely used as a challenge
strain in C. difficile hamster models of infection.29,30 C. difficile was
propagated and spores were prepared as described previously.31–33
Recombinant protein purification
The full-length protein sequence for FliC (NCBI AAD46086.1) was
obtained from C. difficile strain VPI 10463 (ribotype 087; ATCC
43255). The receptor binding domains of TcdA (TcdARBD; NCBI
M30307), and TcdB (TcdBRBD; NCBI P18177) were also identified
and obtained from C. difficile strain VPI 10463.21 The corresponding
nucleotides (fliC, tcdARBD, and tcdBRBD) were codon-optimized for
expression in E. coli, synthesized and sequences were confirmed (Blue
Heron Biotechnologies, Bothell, WA, USA). These nucleotides were
cloned into theNdeI and BamHI sites present on the multiple cloning
site (MCS) of the pET19b bacterial expression vector (EMDMillipore,
Billerica, MA, USA). The pET19b expression vector carries an amino-
terminal (N-terminus) polyhistidine (His) tag containing six His resi-
dues followed by the MCS.
E. coli BL21DE3* competent cells were transformed with the pET19b
expression vectors containing fliC, tcdARBD, or tcdBRBD inserts. The
cultures were grown in Luria Bertani (LB) medium containing ampi-
cillin (100 mg/mL) at 37 6C with aeration. Isopropyl-beta-D-thiogalac-
topyranoside (IPTG; 0.1 mM) was used to induce the expression of the
inserted nucleotides (Sigma Aldrich, St. Louis, MO, USA). The
expressed proteins were purified using Talon His-tag purification resin
according tomanufacturer’s specifications (Clontech Laboratories Inc.,
Mountain View, CA, USA). Protein was detected by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immuno-
blotting using commercial anti-His tag antibody (Life Technologies).
The His-tag was not removed following purification, given the low
immunogenicity of such tags.34,35 Endotoxin was removed by using
Endotrap Blue columns according to manufacturer’s specifications
(Hyglos GmbH, Bernried, Germany). Endotoxin levels present in the
purified recombinant proteins was measured by ToxinSensor Gel Clot
Endotoxin Assay Kit (Genscript, Piscataway, NJ, USA).
Immunization regimen
All animal work was approved by the Institutional Animal Care and
Use Committee at the Rockefeller University, New York.
To study the immunogenicity and adjuvanticity of recombinant FliC,
we immunized cohorts of five female, 8- to 10-week-old, C57/BL6mice
(Jackson Laboratories, Bar Harbor, ME, USA; Table 1). Mice were
intraperitoneally (i.p.) immunized with 25 mg of FliC, adjuvanted with
1:1 by volume of Imject alum (alum) that contains an aqueous solution
of aluminum hydroxide (40 mg/mL) and magnesium hydroxide
(40 mg/mL) plus inactive stabilizers (Life Technologies). Cohorts of
mice were also immunized with a total of 25 mg of TcdARBD and
TcdBRBD, or a total of 25 mg of TcdARBD and TcdBRBD, adjuvanted
with FliC. Cohorts of control mice were immunized with saline. All
cohorts were immunized on days 0, 14, and 28. Blood samples were
collected, and serum was processed and stored from mice on days 0
(naive serum), 14, 28, and 42, as previously described.36 Stool pellets
from eachmouse from all the cohorts were collected on days 3, 4, and 5
following challenge. All cohorts of mice were challenged two weeks
post-last immunization as described below.
In the dose escalation study of recombinant FliC, four cohorts of 8–
10 female, age-matched 8- to 10-week-old, C57BL/6 mice (Jackson
Laboratories, Bar Harbor, ME, USA) were i.p. immunized on days 0,
14, and 28 (three immunizations) or on days 0, and 14 (two immu-
nizations; Table 1). Cohorts of mice received 5 mg or 25 mg total of FliC
adjuvanted with 1:1 by volume of alum. The cohort of control mice
was immunized with saline and 1:1 volume of alum. Blood samples
were collected, serumwas processed, and stored from all the mice 24 h
before challenge and two weeks post-challenge from the surviving
mice. All cohorts of mice were challenged two weeks post-last immun-
ization as described below.
To study the protective efficacy of the recombinant FliC immun-
ization in the hamstermodel of CDI, 5- to 6-week-old (80–100 g)male
Golden Syrian hamsters (Mesocricetus auratus) were obtained from
Harlan and were housed in sterile individual ventilated cages.
Hamsters were i.p. immunized on days 0, 14, and 28 (three immuni-
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zations; Table 1). Cohorts of hamsters (n5 7) received 20 mg or 100 mg
total of FliC adjuvanted 1:1 volume of alum. A separate cohort of
control hamsters (n 5 7) was i.p. immunized with saline and 1:1
volume of alum. Blood was collected, serum was processed, and
stored from hamsters one week before challenge and two weeks
post-challenge from surviving hamsters. Stool pellets from each ham-
ster from all the cohorts was collected one week before challenge All
cohorts of hamsters were challenged three weeks after the last immun-
ization as described below. These experiments were repeated twice
with a total of 14 hamsters in each cohort.
Measurement of serum antibody responses of mice and hamsters
To better standardize the enzyme-linked immunosorbent assay
(ELISAs) for consistency, reproducibility, and accuracy for the detec-
tion of immune responses to FliC, TcdARBD, and TcdBRBD in mice
and hamster serum, we completed a checkerboard dilution series with
various concentrations of mouse and hamster serum.37 We coated
plates with 10 ng/well, 20 ng/well, 50 ng/well, 100 ng/well, 200 ng/well,
and 500 ng/well of commercially available purified TcdA, TcdB (List
Biological Laboratories, Campbell, CA, USA) or recombinant FliC in
50 mM carbonate buffer, pH 9.6 as described elsewhere.21 Briefly, we
blocked plates with PBS-1% bovine serum albumin (BSA; Sigma
Aldrich). We diluted immune and naive sera 1:10, 1:50, 1:250,
1:500, 1:1000, 1:2000, 1:5000, and 1:1:10 000 in PBS containing
0.05% Tween 20 (PBS-T) and 0.1% BSA (Sigma Aldrich). We used
a dilution of 1:500, 1:1000, and 1:2000 of goat anti-mouse immuno-
globulin G (IgG) conjugated with horseradish peroxidase (HRP) and
1:2000, 1:4000, and 1:8000 of goat-anti-hamster IgG conjugated with
HRP to detect bound antibodies (Southern Biotech, Birmingham,
AL). We developed the plates with 2, 2’-azino-bis (3-ethylbenzthiazo-
line-6-sulfonic acid, ABTS; Sigma Aldrich) and 0.03% H2O2 (Sigma
Aldrich) and determined optical density using a Vmax microplate
reader (Molecular Devices Corp, Sunnyvale, CA, USA) at 405 nm
kinetically for 5 min at 14-s intervals, as previously reported.36 We
used a kinetic ELISA where data are expressed as change in milli-
optical density units over time (OD/min).38,39
For the detection of antibody responses to FliC, TcdARBD, and
TcdBRBD, we coated plates with 100 ng/well of purified TcdA,
TcdB, or recombinant FliC in 50 mM carbonate buffer, pH 9.6. For
the detection of anti-FliC, anti-TcdARBD and anti-TcdBRBD
immune responses in serum, we diluted sera 1:1000 in PBS containing
0.05% Tween 20 (PBS-T) and 0.1% BSA.We used a dilution of 1:1000
of goat anti-mouse IgG conjugated with HRP and 1:8000 of goat-anti-
hamster IgG conjugated with HRP to detect bound antibodies. We
developed the plates as mentioned above and determined optical den-
sity via kinetic ELISA. Controls comprised of pooled serum fromnaive
experimental cohorts. All samples were tested in technical duplicate.
CDI model in mice
Mice were challenged via oral gavage two weeks after the last immun-
ization. Mice were given orally administered antibiotic cocktail
(kanamycin 40 mg/kg, gentamicin 3.5 mg/kg, colistin 4.2 mg/kg,
metronidazole 21.5 mg/kg, and vancomycin 4.5 mg/kg) in drinking
water for five days followed with i.p. administered clindamycin
(10 mg/kg) 24 h before challenge. Mice were orally challenged with
106 spores of strainC. difficileUK1 andmonitored daily for 14 days for
changes in weight, diarrhea, morbidity, moribundity and mortality.32
Mice were sacrificed when the following conditions were observed:
rapid or progressive weight loss of greater than 25% of starting weight,
a lack of responsiveness to manual stimulation, immobility, ruffled
fur, hunched position, or signs of diarrhea, such as wet tail.
Culture of C. difficile from mice fecal pellets
Fecal pellets were collected from each mouse on days 3, 4, and 5 post-
challenge for the evaluation of C. difficile colonization. Freshly col-
lected fecal pellets were weighed and stored in PBS at –80 6C.40 Spore
Table 1 Mice and hamster study design
Study Immunization cohort Immunization dose Intraperitoneal immunization
(i.p.) schedule
Number of
animals
Orogastric challenge
Immunogenicity and
adjuvanticity study in mice
FliC 25 mg FliC1 1:1 volume of Alum Three immunizations on days
0, 14, 28
5 106 spores of strain C. difficile
UK1 on day 42
TcdARBD1 TcdBRBD 25 mg TcdARBD1 TcdBRBD Three immunizations on days
0, 14, 28
5 106 spores of strain C. difficile
UK1 on day 42
TcdARBD1 TcdBRBD1
FliC
25 mg TcdARBD1 TcdBRBD1
FliC
Three immunizations on days
0, 14, 28
5 106 spores of strain C. difficile
UK1 on day 42
Control Saline1 1:1 volume of Alum Three immunizations on days
0, 14, 28
5 106 spores of strain C. difficile
UK1 on day 42
Dose escalation
study in mice
FliC 25 mg3 3 25 mg FliC1 1:1 volume of Alum Three immunizations on days
0, 14, 28
9 106 spores of strain C. difficile
UK1 on day 42
FliC 25 mg3 2 25 mg FliC1 1:1 volume of Alum Two immunizations on days 0,
14
10 106 spores of strain C. difficile
UK1 on day 28
FliC 5 mg3 3 5 mg FliC1 1:1 volume of Alum Three immunizations on days
0, 14, 28
10 106 spores of strain C. difficile
UK1 on day 42
FliC 5 mg3 2 5 mg FliC1 1:1 volume of Alum Two immunizations on days 0,
14
10 106 spores of strain C. difficile
UK1 on day 28
Control Saline1 1:1 volume of Alum Three immunizations on days
0, 14, 28
8 106 spores of strain C. difficile
UK1 on day 42
Protective efficacy
study in hamsters
FliC 100 mg3 3 100 mg FliC1 1:1 volume of Alum Three immunizations on days
0, 14, 28
14 (71 7) 500 cfu of C. difficile strain
630Derm on day 49
FliC 20 mg3 3 20 mg FliC1 1:1 volume of Alum Three immunizations on days
0, 14, 28
14 (71 7) 500 cfu of C. difficile strain
630Derm on day 49
Control Saline1 1:1 volume of Alum Three immunizations on days
0, 14, 28
14 (71 7) 500 cfu of C. difficile strain
630Derm on day 49
FliC vaccination against C. difficile infection
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counts of C. difficile were calculated by combining fecal samples of
eachmouse and plating serial dilutions on cycloserine-cefoxitin fruct-
ose agar plates with horse blood and taurocholate (CCFA-HT;
Anaerobe Systems, Morgan Hill, CA, USA). Plates were incubated
anaerobically for 48 h. Grayish-white colonies weremanually counted.
Passive transfer of polyclonal anti-FliC antibodies in mice
Ten female, 8- to 10-week-old, C57/BL6 mice were i.p. immunized
three times every two weeks with 25 mg of FliC adjuvanted with alum.
Hyperimmune serum was collected two weeks after the last immun-
ization. Anti-FliC-specific serum IgG levels were measured by using a
FliC-specific ELISA.
w?>Ten naive age-matched 8- to 10-week-old, C57BL/6 mice were
given orally administered antibiotic cocktail (kanamycin 40 mg/kg,
gentamicin 3.5 mg/kg, colistin 4.2 mg/kg, metronidazole 21.5 mg/kg,
and vancomycin 4.5 mg/kg) in drinking water for 5 days followed with
i.p. administered clindamycin (10mg/kg) 24 h before challenge. At the
time of clindamycin administration, 400 mL of FliC-specific hyperim-
mune serumwas i.p. administered to fivemice and 400 mL naive serum
from unimmunized mice was given to the remaining five mice by i.p.
administration. Twenty-four hours post-passive transfer of hyperim-
mune or naive serum, all 10micewere challengedwith 106 UK1 spores,
as described above. Bloodwas collected at the time of passive transfer (t
5 0), day 1 (at time of challenge), day 3, day 7, and day 10, to study the
level of circulating FliC-specific serum IgG in the blood. Following oral
challenge, mice were monitored daily for 14 days as mentioned above.
CDI model in hamsters
Hamsters were challenged three weeks after last immunization. All
hamsters were dosed orogastrically with clindamycin (30 mg/kg)
and infected five days later with 500 colony-forming units (CFU) of C.
difficile strain 630Derm. Following oral challenge, hamsters were mon-
itored every eight h for signs of disease progression for the duration of
14 days. Hamsters were sacrificed when the following conditions were
observed: rapid or progressive weight loss of greater than 20%, a sign of
recumbancy, such as leaning or having a hunched position, a lack of
responsiveness to manual stimulation, or signs of diarrhea.
Analysis of 16S rRNA fecal bacterial communities in hamsters
Fresh fecal samples were collected from hamsters one week prior to
challenge and genomic DNA was prepared from each hamster using
the Qiagen QIAamp DNA Stool Mini kit (Qiagen, Valencia, CA,
USA). We amplified the bacterial 16S rRNA V1-V2 hypervariable
region from the genomic DNA using the forward primer 8F (AGA
GTT TGA TCC TGG CTC AG) fused with the Ion Torrent Adaptor A
sequence and 1 of 23 unique 10 base pair (bp) barcodes, and reverse
primer 357R (CTG CTG CCT YCC GTA) fused with the Ion Torrent
Adaptor P1 from each fecal sample.41 Polymerase chain reactions
(PCR) were performed using Platinum PCR SuperMix (Life
Technologies) with the following cycling parameters: 94 6C for 10
min, followed by 30 cycles of 94 6C for 30 s, 53 6C for 30 s, 72 6C for
30 s, and a final elongation step of 72 6C for 10 min. Resulting ampli-
cons were purified on a 2% agarose gel stained with SYBR Safe (Life
Technologies) using the MinElute PCR Purification kit (Qiagen).
Amplicons were further purified with Ampure beads (Beckman-
Coulter, Brea, CA, USA), and molar equivalents were determined
for each sample using a Bioanalyzer 2100 HS DNA kit (Agilent
Technologies, Santa Clara, CA, USA). Samples were pooled into equi-
molar proportions and sequenced on 314 chips using an Ion Torrent
PGM according to manufacturer’s instructions (Life Technologies).42
Resulting sequence reads were removed from the analysis if they were
,180 bp, had any barcode or primer errors, contained any ambiguous
characters, or contained any stretch of.8 homopolymers. Sequences
were assigned to their respective samples based on a 10-nucleotide
barcode sequence, and were analyzed further using the Qiime pipe-
line.43 Briefly, representative Operational Taxonomic Units (OTU)
from each set were chosen at a minimum sequence identity of 97%
using UClust44 and aligned using PyNast45 against the Greengenes
database.46 Multiple alignments then were used to create phylogenies
using FastTree47, and taxonomy was assigned to each OTU using the
Ribosomal Database Project (RDP) classifier.48,49 Principal coordi-
nates analysis (PCoA) was performed based on Beta Diversity using
weighted Unifrac distances.50
Statistical analysis
For normally distributed data, we used an unpaired Student t-test
analysis for comparison of means; for nonparametric data, we used
the Mann–Whitney U-test. We performed statistical analyses using
Microsoft Excel 2002 and plotted graphs using GraphPad Prism
(GraphPad Software, San Diego, CA, USA). A P-value of less than
0.05 was considered to indicate statistical significance. Kaplan–
Meier plots were used to analyze survival in the challenged mice,
Mantel–Cox test for pairwise comparisons and Gehan Breslow
Wilcoxon test was used to assess statistical significance between the
cohorts.
RESULTS
Cloning, expression and purification of recombinant C. difficile
flagellar proteins FliC
We purified recombinant FliC (0.14 mg/mL) from E. coli using the
pET19b expression plasmid. FliC was expressed as a 38 kDa protein
(Figure 1A). Endotoxin levels were confirmed to be less than 5 endo-
toxin units/mL (EU/mL) in the purified protein samples. SDS-PAGE
followed by Coomassie Blue staining confirmed the purity of recom-
binant FliC (Figure 1A, left panel). The identity of the His-tagged
recombinant C. difficile flagellar protein FliC was confirmed by
Western blot analysis using a anti-His monoclonal antibody
(Figure 1A, right panel). TcdARBD and TcdBRBD were purified for
an earlier study, and the purity of these proteins has been shown by
SDS-PAGE elsewhere.21
Immunogenicity and adjuvanticity of recombinant C. difficile
flagellar protein FliC
For the detection of anti-FliC, anti-TcdARBD, and anti-TcdBRBD
immune responses in serum by ELISA, 100 ng/well of recombinant
FliC as capture antigen, mice or hamster serum dilutions of 1:1000, a
1:1000 dilution of goat anti-mouse IgG conjugated with HRP and a
1:8000 dilution of goat anti-hamster IgG conjugated with HRP pro-
vided consistent and accurate results (see Materials And Methods
Section). A kinetic ELISA was used since this method produced true
quantitative results requiring fewermultiple dilutions (data not shown).
Recombinant FliC was found to be immunogenic in mice, especially
following two immunizations (P , 0.05, mean OD/min 5 0.134 fol-
lowing two immunizations compared to mean OD/min5 0.05 follow-
ing one immunization; Figure 1B). In mice that were immunized with
FliC alone, a third immunization did not significantly improve the anti-
FliC immune response in the serum of these mice compared to two
immunizations IgG (P5 0.3429, meanOD/min5 0.134 following two
immunizations compared to mean OD/min 5 0.173 following
three immunizations). This immune response was specific for FliC, as
FliC vaccination against C. difficile infection
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we do not see cross-reactive responses in mice immunized with
TcdARBD and TcdBRBD (mean OD/min 5 0.002, following
three immunizations).51 Additionally, in the FliC-specific ELISA,
cross-reactivity due to the presence of the low-immunogenic His-tag
on the immunogen (TcdARBD and TcdBRDB) and the coating antigen
(FliC) was not observed. Cohorts of mice that received FliC adjuvanted
with alum had comparable levels of anti-FliC IgG levels to the cohort of
mice that received TcdARBD and TcdBRBD in the presence of FliC
following the second and the third immunizations (Figure 1B).
Next, we wanted to test the adjuvant properties of recombinant
FliC. Following immunization with TcdARBD and TcdBRBD in the
presence of FliC, mice were able to mount a stronger anti-TcdARBD
IgG immune response (mean OD/min5 0.06) in serum compared to
mice that received TcdARBD and TcdBRBDwith no additional adjuv-
ant help (mean OD/min5 0.02; Figure 1C). This significant enhance-
ment of anti-TcdARBD IgG response was evident following the first
boost (P , 0.05). This enhancement was not observed for anti-
TcdBRBD IgG responses. Similar levels of anti-TcdBRBD IgG res-
ponse were observed in the cohort that received TcdARBD and
TcdBRBD adjuvanted with FliC and the cohort that received
TcdARBD and TcdBRBD with no additional adjuvant help (P 5
NS; Figure 1D).
Protective efficacy of recombinant C. difficile flagellar protein FliC
and the receptor binding domains of TcdA and TcdB
To test whether the recombinant FliC was able to induce a protective
immune response, immunized mice from the previous experiments
were challengedwithC. difficile twoweeks after the last immunization.
The cohort of mice that was immunized with recombinant flagellar
protein FliC adjuvanted with alum demonstrated 100% protection
against CDI following challenge with a heterologous, clinically rel-
evant C. difficile strain, UK1 (Figure 2A). Cohorts of mice immunized
with TcdARBD and TcdBRBD alone or adjuvanted with FliCwere also
afforded 100% protection and remained completely disease-free until
the end of the study when these mice were euthanized. In comparison,
the control mice all succumbed to CDI by day 8 (P5 0.003). Hunched
posture, ruffled fur, and signs of wet tail were observed in individual
mice that were euthanized.
To test whether immunizationwith FliCwould have an effect on the
levels of spore shedding in C. difficile-challenged mice, we compared
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Figure 1 Immunogenicity and adjuvanticity of recombinant C. difficile flagellar protein FliC in mice. (A) 2 mg of purified recombinant C. difficile flagellar protein FliC
was analyzed by SDS-PAGE on a gel stained with Coomassie blue (left panel). Whole cell lysate from uninduced and IPTG-inducedBL21 (DE3)* cells were analyzed by
Western blot using anti-His antibody (right panel). M, molecular weight markers; I, IPTG-induced cell lysate; U, uninduced cell lysate. Serum anti-FliC IgG (B), anti-
TcdA IgG (C), and anti-TcdB IgG (D) responses in mice immunized on days 0, 14, and 28 in serum collected on days 14, 28, and 42. Cohorts of mice received 25 mg
total of FliC adjuvanted with alum, unadjuvanted TcdARBD, and TcdBRBD or TcdARBD and TcdBRBD adjuvanted with FliC. Results were determined by kinetic
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Figure 2 Survival and spore shedding in FliC-immunized mice following C. dif-
ficile UK1 challenge. (A) Survival in vaccinated C57BL/6 mice following orogas-
tric challengewith 106 CFU ofC. difficile strainUK1. Cohorts ofmice received 25
mg total of FliC adjuvanted with alum, unadjuvanted TcdARBD, and TcdBRBD or
TcdARBD and TcdBRBD adjuvanted with FliC. Control mice were immunized
with saline. Mice were immunized on day 0, 14, and 28 and challenged two
weeks after the last immunization following antibiotic treatment. Mantel–Cox test
for pairwise comparisons and Gehan Breslow Wilcoxon test was used to assess
statistical significance between the cohorts. (B) C. difficile shedding in mouse
fecal samples from immunized and control mice following orogastric challenge
with 106 CFU of C. difficile strain UK1. Results denote fecal shedding of
C. difficile reported as CFU per gram (the geometric mean plus standard error
of the mean) from fecal pellets. One fecal pellet was collected on days 3, 4, and 5
post-challenge from every mouse in each cohort containing five mice. * denotes
statistical significance (P , 0.05), using an unpaired Student t-test analysis for
comparison of means.
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the levels of spores present in the in fecal pellets of immunized and
control mice over a period of three days, starting from day three.
Cohorts of mice immunized with TcdARBD and TcdBRBD alone or
adjuvanted with FliC and the cohort of mice that was immunized with
FliC adjuvanted with alum shed similar levels of C. difficile in their
stool (P 5 NS; Figure 2B). All cohorts of immunized mice had sig-
nificantly lower levels of C. difficile in their stool compared to control
mice for up to day 5 post-challenge following which the control mice
began to succumb to disease (P , 0.05; Figure 2B).
Dose–response effect of recombinant C. difficile flagellar protein
FliC on protective efficacy in mice
To further study the effect of dose–response and the number of immu-
nizations on the protective efficacy of recombinant FliC, we immu-
nized mice with a low or a high dose of FliC, either 5 mg or 25 mg, and
varied the number of doses to either two or three i.p. immunizations,
followed by heterologous challenge with C. difficile strain UK1
(Figure 3). The first symptoms of CDI presented on day 5 in four
control mice, twomice immunized twice with 25 mg of FliC, and three
mice each immunized with five mg of FliC either twice or three times
(Figure 3A). The cohort of mice that received 25 mg of FliC and a total
of three doses had the highest protective efficacy of 89%,with eight out
of nine mice remaining disease-free following the challenge with
C. difficile until the end of study when they were euthanized (P ,
0.05, when compared to the control cohort). The cohort of mice that
received 25 mg of FliC and a total of two doses had a protective efficacy
of 50% (P, 0.05, when compared to the control cohort). Cohorts of
mice that received 5 mg of FliC and three doses had a protective efficacy
of 70% (P, 0.05, when compared to the control cohort). Cohorts of
mice that received 5 mg of FliC twice had 40% protective efficacy (P5
0.01, when compared to the control cohort). Protective efficacy of
the recombinant FliC vaccine also correlated with weight loss, with
the cohort ofmice receiving 25 mg of FliC and a total of three doses had
the least weight loss due to diarrhea and colitis, as compared to the
mice in the control cohort for days 4 and 6 (P , 0.005; Figure 3B).
Mice that were euthanized that had greater than 20%weight loss, signs
of diarrhea on their tail, and such symptoms were accompanied with a
hunched posture and low levels ofmobility. At day 7, the last surviving
control mouse was weighed and euthanized, and changes in weight
were no longer measured for the other surviving mice.
To correlate protection inmice with level of antibodies present in the
blood, we looked for the presence of anti-FliC IgG in the serum of mice
24 h before challenge (Figure 3C). Mice that were immunized with the
high 25 mg dose of FliC, either two (mean OD/min 5 0.054) or three
(mean OD/min 5 0.083) times, as well as mice that were immunized
three times with the low 5 mg dose of FliC (mean OD/min 5 0.051),
were able to mount a significantly stronger anti-FliC IgG response
compared to the cohort that was immunized twice with the low 5 mg
dose of FliC (mean OD/min5 0.005; P, 0.05). Additionally, mice in
all cohorts that succumbed to challenge withC. difficile had lower levels
of anti-FliC IgG in their serum 24 h before challenge than protected
mice (mean OD/min 5 0.001 vs. 0.081, P , 0.001; Figure 3C). Two
weeks post-challenge, anti-FliC IgG was detected in the serum of all
survivingmice. Anti-FliC IgG response was significantly higher only for
the cohort of mice that received 25 mg of FliC two times, compared to
anti-FliC IgG levels before challenge (P , 0.05; data not shown).
Effect of passive transfer of mouse anti-FliC-specific polyclonal
antibodies on the protective efficacy in mice
To assess the impact of FliC-specific antibodies on the protection
against C. difficile challenge, hyperimmune serum was collected from
mice immunized with recombinant FliC. The hyperimmune serum
had an OD/min value of 0.345 using an anti-FliC IgG-specific ELISA.
Based on our previous challenge experiments (Figure 3C), a measure-
able circulating anti-FliC IgG serum titer of greater than 0.0255
OD/min is required for 100% protection against C. difficile UK1.
We transferred 400 mL of hyperimmune serum with an OD/min value
of 0.345 to naive mice that were then challenged with C. difficile UK1
24 h post-infusion. Accounting for the total blood volume of an 8- to
10-week-old, C57/BL6 mouse to be two mL, a fivefold dilution of the
infused hyperimmune serumwould lead to a circulating anti-FliC IgG
serum titer of 0.069 OD/min, which is still 2.7-fold greater than the
protective titer needed for 100% protection.
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Figure 3 Anti-FliC IgG dose response and survival in FliC immunized mice challenged with C. difficile UK1. (A) Survival in vaccinated C57BL/6 mice following
orogastric challenge with 106 CFU of C. difficile UK1. Cohorts of mice received either 5 mg or 25 mg total of FliC adjuvanted with alum. Control mice were immunized
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FollowingC. difficileUK1 challenge, four out of five controlmice that
received 400 mL naive serum succumbed toC. difficile challenge between
three and seven days post-challenge (Figure 4A). Signs of morbidity,
such as hunched posture and ruffled fur were observed, alongwith signs
of diarrhea and weight loss, and these mice were euthanized. Passive
transfer of hyperimmune polyclonal anti-FliC serumwas able to protect
four out of five mice from infection followingC. difficile challenge (P,
0.05 compared to the naive serum-treatedmice). Passively administered
anti-FliC antibody titers were detected in four out of five mice at the
time of infection and until day 10 (Figure 4B).
Protective efficacy of recombinant C. difficile flagellar protein FliC
in the hamster model of CDI
Golden Syrian hamsters have been extensively used to study CDI due
to their high level of susceptibility to C. difficile following the admin-
istration of antibiotics. To evaluate the protective efficacy of the
recombinant FliC, hamsters were immunized and challenged with
C. difficile 630Derm as shown in Figure 5. Based on our initial findings
in the murine model (Figure 3A), cohorts were given three i.p. immu-
nizations of either a low dose of 20 mg or a high dose of 100 mg of
recombinant FliC adjuvanted with alum. The immunization dose of
the low and high group reflect the dose adjustment due to the weight
differences between mice and hamsters, which is approximately four-
fold to fivefold. We observed that all animals in the control group that
was immunizedwith saline and alumdeveloped symptoms of CDI and
were euthanized within 2–7 days after challenge with C. difficile
630Derm (Figure 6A). Hamsters were euthanized when signs of diar-
rhea were observed, such as wet tail, or had lost greater than 20% of
their body weight. In the vaccinated cohorts, 8 out of 14 hamsters in
the high dose group (43% survival) succumbed to CDI as compared to
5 out of 14 in the low dose group (64% survival). Mantel–Cox analysis
revealed no statistically significant differences in the survival between
the two vaccinated cohorts (P5 0.349) whereas the high dose and the
low dose cohorts were significantly different from the control (P ,
0.05). To test for correlations between the observed partial protection
in hamsters and the level of circulating anti-FliC IgG present in the
blood, we assessed the anti-FliC IgG in the serum of hamsters 1 week
before challenge (Figure 6B). Irrespective of the dose the hamsters
received, both cohorts had similar levels of anti-FliC IgG in their
serum. We were also unable to detect any anti-toxin IgG in the serum
of surviving hamsters two weeks post-challenge (data not shown).
We also characterized fecal bacterial communities in hamsters
immunized with the recombinant FliC one week before challenge to
determine whether immunization with FliC may have adversely affec-
ted their gut microbiota. Using PCoA, we observed that there were no
distinguishing features of the fecal gut microbiota associated with the
use of the recombinant vaccine when compared to control hamsters
that did not receive the vaccine (Figure 6C).
DISCUSSION
Flagellum plays an important role in adhesion to mucus cells and
colonization in several bacterial species such as Helicobacter pylori,
V. cholerae, and Pseudomonas aeruginosa.52 Flagella-mediated mot-
ility, adherence and biofilm formation are important virulence factors
that contribute to the overall fitness of pathogens, especially gastro-
intestinal pathogens. For C. difficile, the role of flagella in motility,
adherence, and biofilm formation is strain-specific. For example,
C. difficile strain R20291, a PCR ribotype 027 (B1/NAP1) hyperviru-
lent strain isolated during an outbreak in the UK, is found to be
monotrichously flagellated, with flagellum playing a role in coloniza-
tion, adherence, and higher biofilm formation in vitro.15,53 This is in
contrast to the widely used clinical strain C. difficile 630Derm which
has peritrichous flagella, adhere less effectively and form a smaller
biofilm in vitro.28 In this study, C. difficile strain 630Derm was able
to cause CDI in hamsters starting at 48 h.
Given the importance of flagella in the virulence ofC. difficile, active
immunization of a susceptible host using C. difficile flagellar compo-
nents in addition to TcdARBD and TcdBRBD could provide both a
preventive and a therapeutic vaccine strategy by reducing or prevent-
ing bacterial colonization as well as preventing toxin-induced disease
symptoms. Here we also report that mice immunized with TcdARBD
and TcdBRBD adjuvanted with FliC had significantly higher anti-FliC
IgG responses in the serum (Figure 1B and 1C) than the cohorts that
received FliC adjuvanted with alum. The use of a single antigen with-
out the aid of an additional adjuvant such as alum makes FliC an
attractive vaccine candidate.21,54 For certain bacterial pathogens,
such as H. pylori, persistence in their human host is possible by
immune evasion. One such mechanism employed by H. pylori is to
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Figure 4 Protection of passively immunized C57BL/6 mice from challenge with
C. difficile UK1. (A) Survival in passively immunized C57BL/6 mice following
orogastric challenge with 106 CFU of C. difficile UK1. Cohorts of mice received
either 400 ml total of hyperimmune FliC serum or naı¨ve serum. Antibiotic-treated
mice were transfused on day 0 and challenged 24 h later. Mantel–Cox test for
pairwise comparisons and Gehan Breslow Wilcoxon test was used to assess stat-
istical significancebetween the cohorts. (B) Detectionof circulating anti-FliC IgGon
days 1, 3, 7, and 10 in serum ofmice passively immunizedwith hyperimmune FliC
serum. Results were determined by kinetic ELISA and are reported as OD per
minute. Numbers denote individual mice. Mouse 178 succumbed to challenge
on day 7, therefore no serum sample was collected for days 7 and 10.
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have flagellum that are less proinflammatory and do not activate
TLR5.55 AlthoughC. difficile FliC does activate TLR5 and has adjuvant
properties associated with its TLR5 activation, this activation is at a
much lower level than that observed with S. Typhimurium FliC, and
immune evasion may be a reason for this.21 In this study, FliC does
induce an adaptive immune response in mice and hamsters and is
found to have adjuvant properties in the context of TcdARBD, but
not with TcdBRBD. It is possible that the anti-TcdB IgG response is
maximally adjuvanted with the co-administered TcdARBD, as it has
been reported previously that TcdA has innate adjuvant properties.56
Whether C. difficile FliC-mediated activation of TLR5 plays a signifi-
cant role in inducing innate immune responses against C. difficile was
not addressed in our current study.
Bacterial challenge experiments in mice are restricted to a few
C. difficile strains that can consistently infect and cause CDI in mice.
Inmost cases, the strainVPI 10463,which expresses high levels of toxin
A and B production, has low sporulation rates, and does not cause
colitis in humans, has been used as the challenge strain.57 To more
closelymimic the human disease, we have used a hypervirulent clinical
strain, C. difficile strain, UK1 (027/B1/NAP1 strain) in our mice chal-
lenge model. The induced anti-FliC IgG response was protective in
88–100% of the mice following heterologous challenge withC. difficile
UK1 in two separate challenge experiments in mice. FliC-immunized
mice also shed fewerC. difficile spores in their stool between days 3 and
5 post-challenge. Although C. difficile spores are shed in the feces of
mice for up to three weeks post-challenge, C. difficile spores rapidly
transit through the gastrointestinal tract of mice and can be found in
the feces of mice as early as four days, with the numbers significantly
waning between days 7 and 10. In our current study, we analyzed
whether vaccination with recombinant FliC orwith the RBDs of toxins
could lead to a difference in the level of shedding ofC. difficile spores in
these cohorts. Given that the control animals succumbed to CDI from
day 6 post-challenge, for comparison between cohorts we restricted
our study to the initial days post-challenge. Whether vaccination
with a recombinant FliC vaccine prevents asymptomatic carriage of
C. difficile following exposure needs to be further studied.
Protection from CDI and death in immunized mice correlated with
a dose–response and the number of immunizations received, as well as
the antibody titer levels before challenge. The mice that succumbed to
challenge had lower levels of anti-FliC IgG response compared to those
that survived. This phenomenon was observed across all cohorts of
mice, suggesting that a strong anti-FliC IgG response is a correlate of
protection in these immunized mice. Transfer of passive anti-FliC
immunity in the form of hyperimmune polyclonal anti-FliC antibod-
ies mediated protection against C. difficile challenge in four out of five
mice, further underscoring the protective role of an adaptive immune
response against C. difficile FliC. The mechanism by which parenter-
ally induced IgG reaches the mucosal surface of the gut where
C. difficile is present is unclear. One hypothesis is that FcRn receptors
present in the epithelial cells of the gut are able to transport IgG across
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Figure 5 Experimental design of immunization and protective efficacy experiments in male Golden Syrian hamsters.
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the intestinal epithelium or that small amounts are synthesized loc-
ally.58,59 A new model of protection against CDI in the gut lumen by
systemic antibodies suggests that the transport of antibodies across the
gut wall is not solely Fc-dependent but is due in part to the paracellular
transport of systemic antibodies following toxin-mediate damage to
the gut epithelium.60
Irrespective of the mechanism of protection and the site where
circulating serum antibodies neutralize C. difficile, clinical studies
and human studies continue to confirm the importance of circulating
serum IgG in the protection against CDI.6,61,62 The importance of a
mucosally induced IgA response in the protection from CDI remains
unclear, and recent studies indicate that systemic IgG responses may
be more important in determining clinical outcomes in CDI.5,6,63
Nevertheless, it would be beneficial for a parenteral vaccine to induce
both a systemic and a mucosal immune response. We have previously
demonstrated that a mucosal adjuvant such as a non-toxic mutant of
E. coli heat labile enterotoxin, LT (r192g) is needed to induce a potent
mucosal immune response in the form of IgA present in the stool of
toxin-immunized mice.21,36 Further studies need to be performed to
delineate the mechanism of protection of anti-FliC-induced IgA
against CDI using mucosal adjuvants.
We confirmed our findings in mice with protective efficacy experi-
ments in two separate challenge experiments in hamsters using strain
C. difficile 630Derm.C. difficile 630Derm is a well-characterized clinical
strain that consistently causes CDI in hamsters.64 Golden Syrian ham-
sters express TLR5 receptors (NCBI GeneID: 101829185) making this
an appropriate model to confirm our previous results. In the hamster
challenge experiments, we tested two doses based on our initial mouse
experiments in which 5 mg or 25 mg of FliC given three times afforded
high levels of protection. However, both cohorts of hamsters, given
either a high or a low dose, had comparable levels of anti-FliC anti-
bodies 1 week before challenge and were afforded partial protection
against C. difficile 630Derm challenge. The observed level of protective
efficacy of recombinant FliC in hamsters is comparable to other
C. difficile surface antigens that have been tested in hamsters as vaccine
candidates such as Cwp84 and the S-layer protein, SlpA (33% and 66%
protective efficacy, respectively).65,66
Flagellin is highly variable across species. For example: Bacillus sp.
C-125 flagellin is 31 kDa, E. coli flagellin is 51 kDa, and B. subtilis
flagellin is 32 kDa. The smaller-sized flagellin lack an outer molecular
domain present in higher molecular weight flagellin. Although highly
variable, bacterial flagella share common epitopes due to their ability
to globally activate TLR5. Anti-flagellin antibodies have been shown to
be cross-reactive across different bacterial species due to these com-
monly shared epitopes and dysbiosis of the gut microflora may render
the host more susceptible to pathogens such as C. difficile.67 We show
here that using aC. difficile flagellin vaccination strategy does not have
a significant impact on the membership of the fecal microbiome in
hamsters and likely plays no role in inhibiting colonization of the
indigenous bacterial communities of the hamster. These results sug-
gest that any effects of the recombinant FliC vaccine were not
mediated through changes in the bacterial membership of the gut
microbiome. Moreover, patients who have CDI are able to mount
an anti-FliC immune response but at the resolution of CDI, are still
able to have a normal, functional gut thus showing no long-term side-
effects of a natural anti-FliC immune response.68
Several studies suggest that toxin production in C. difficile is modu-
lated positively, by genes from the flagellar (F)3 regulon, and nega-
tively, by genes from the F1 region.3,14 Evidence also suggests that
toxin expression is directly influenced by sigma factor D (SigD), the
flagellar-specific sigma factor.69 It has been reported that inactivation
of fliC, present in the F1 region of the flagellar regulon, leads to the
overproduction of toxins in culture supernatants.14 To address
whether vaccination of mice by the flagellar protein FliC would have
an adverse effect on immunized mice leading to the production or
even overproduction of toxins following challenge, we looked for anti-
toxin IgG immune responses inmice that survived challenge. We were
unable to detect any anti-toxin IgG in the serum of surviving mice 2
weeks post-challenge (data not shown). Additionally, mice that
received multiple, higher doses of FliC had the highest survival rate,
thus proving that there was no enhancement of infection due to toxin
production from FliC vaccination.
The virulence of C. difficile is due to complex multifactorial inter-
play between several known virulence factors including the toxins and
the flagellar proteins. TcdA and TcdB are essential for symptomatic
disease, whereas the flagellar proteins are involved in motility, biofilm
formation and toxin production.14,70 A vaccine strategy that targets
single or multiple factors needed for colonization, persistence and
toxin production presents a significant advantage over other vaccines
currently in development. Our strategy of targeting the flagellar com-
ponents, especially FliC, may have the capacity to counteract bacterial
attachment and persistence and prevent symptomatic disease, and
therefore, warrants further testing as a potential vaccine candidate.
Further studies are currently ongoing to delineate the mechanism of
protection of anti-FliC-induced antibodies against CDI.
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